About Entrez
Text Version
Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities
PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries LinkOut Cubby
Related Resources Order Documents NLM
Gateway TOXNET Consumer
Health Clinical Alerts ClinicalTrials.gov PubMed
Central
|
|
-
Inhibiting Activities of the
Secondary Metabolites of Phlomis brunneogaleata against Parasitic
Protozoa and Plasmodial Enoyl-ACP Reductase, a Crucial Enzyme in Fatty
Acid Biosynthesis.
Kirmizibekmez H, Calis I,
Perozzo R, Brun R, Donmez AA, Linden A, Ruedi P, Tasdemir
D.
Department of Pharmacognosy, Faculty of Pharmacy,
Hacettepe University, Ankara, Turkey.
Anti-plasmodial
activity-guided fractionation of Phlomis brunneogaleata (Lamiaceae) led
to the isolation of two new metabolites, the iridoid glycoside,
brunneogaleatoside and a new pyrrolidinium derivative (2 S,4
R)-2-carboxy-4-( E)- p-coumaroyloxy-1,1-dimethylpyrrolidinium inner salt
[(2 S,4 R)-1,1-dimethyl-4-( E)- p-coumaroyloxyproline inner salt].
Moreover, a known iridoid glycoside, ipolamiide, six known
phenylethanoid glycosides, verbascoside, isoverbascoside, forsythoside
B, echinacoside, glucopyranosyl-(1-->G (i)-6)-martynoside and
integrifolioside B, two flavone glycosides, luteolin 7- O-beta-
D-glucopyranoside ( 10) and chrysoeriol 7- O-beta- D-glucopyranoside (
11), a lignan glycoside liriodendrin, an acetophenone glycoside
4-hydroxyacetophenone 4- O-(6'- O-beta- D-apiofuranosyl)-beta-
D-glucopyranoside and three caffeic acid esters, chlorogenic acid, 3-
O-caffeoylquinic acid methyl ester and 5- O-caffeoylshikimic acid were
isolated. The structures of the pure compounds were elucidated by means
of spectroscopic methods (UV, IR, MS, 1D and 2D NMR, [alpha] (D)) and
X-ray crystallography. Compounds 10 and 11 were determined to be the
major anti-malarial principles of the crude extract (IC (50) values of
2.4 and 5.9 microg/mL, respectively). They also exhibited significant
leishmanicidal activity (IC (50) = 1.1 and 4.1 microg/mL, respectively).
The inhibitory potential of the pure metabolites against plasmodial
enoyl-ACP reductase (FabI), which is the key regulator of type II fatty
acid synthases (FAS-II) in P. falciparum, was also assessed. Compound 10
showed promising FabI inhibiting effect (IC (50) = 10 microg/mL) and
appears to be the first anti-malarial natural product targeting FabI of
P. falciparum. Abbreviations. ACP:Acyl Carrier Protein CC:Column
Chromatography FabI:Enoyl-Acyl Carrier Protein Reductase FAS-I:Type I
Fatty Acid Synthase System FAS-II:Type II Fatty Acid Synthase System
MPLC:Medium Pressure Liquid Chromatography
PMID: 15326547 [PubMed
- in process]
|